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ABSTRACT
Objective: The present research aims at formulating a mouth dissolving sublingual film of fixed dose combination of doxylamine succinate (DS) and 
pyridoxine hydrochloride (PH) that would provide faster onset of action and hence relief from the condition of nausea and vomiting in pregnancy.
Methods: Mouth dissolving films were prepared using a solvent casting technique. A 23 full-factorial design of eight formulations was set up with three 
independent variables: X1 - polymer 1 HPMC E15 concentration, X2 - polymer 2 HPMC E5 concentration, and X3 - plasticizer PEG 400 concentration. 
The responses, i.e., dependent variables measured for the study were Y1 disintegration time in seconds, Y2 tensile strength in kg/cm2, Y3 drug release 
in the percentage of DS, and Y4 drug release in the percentage of PH. All the formulations were evaluated for physicochemical parameters such as 
clarity, weight, thickness, folding endurance, surface pH, and content. The design expert software 11.0 trial version was used for statistical analysis 
of the responses.
Results and Conclusion: All the film formulations were found to be transparent, non-tacky, and easily peelable having the satisfactory tensile strength 
and folding endurance. The concentration of polymer 1 and 2 was found to have a significant effect on disintegration time and drug release of mouth 
dissolving films. The best film formulation DP1 was found to have a disintegration time of 77.66 s and found to release 96.22% of DS and 95.43% of 
pyridoxine HCl in 21 min.
Keywords: Sublingual film, Mouth dissolving film, Doxylamine succinate, Pyridoxine hydrochloride.
INTRODUCTION
Nausea, a feeling of impending vomiting, is common in pregnancy [1]. 
Around 70–80% of the women, during their first trimester in pregnancy, 
suffer from nausea and vomiting. Nausea and vomiting in pregnancy 
(NVP) can be mild to moderate. Severe NVP may indicate a condition of 
hyperemesis gravidarum [2]. Hyperemesis gravidarum is characterized 
by persistent vomiting, dehydration, ketonuria, electrolyte abnormalities 
(hypokalemia), and weight loss of more than 5%. This deteriorates 
the pregnant woman’s quality of life [3]. The American College of 
Obstetricians and Gynecologists recommend the administration of 
pyridoxine hydrochloride (PH) or combination with doxylamine succinate 
(DS) for the prevention and treatment of NVP [4]. This combination of PH 
(Vitamin B6) and DS is given as first-line treatment as it is found to be safe 
and effective. Antiemetic drugs, PH, is chemically 5-hydroxy-6-methyl-3,4-
pyridinedimethanol hydrochloride (Fig. 1) and DS is N,N-dimethyl-2[1-
phenyl-1-(2-pyridinyl) ethoxy]-butanedioate (Fig. 2) [4].
Antiemetic drugs, DS and PH, are a synergistic combination available 
in the market as a delayed release tablet. The drugs are released and 
absorbed in the intestine, which results in delay in the onset of action, 
and as such, the pregnant women are required to take this medication 
at night so that morning sickness can be prevented. There is a need to 
provide faster onset of action to pregnant women who require relief 
from this condition. Sublingual route is rich in blood supply, and the 
absorption is 3–10 times greater than conventional oral route. It 
bypasses hepatic metabolism and provides for drug absorption directly 
in the systemic circulation [5]. The present study attempts to exploit the 
advantages of sublingual route by the administration of DS and PH in 
the form of sublingual film that would provide faster bioavailability and 
onset of action and use of the film only if the symptom of nausea exists.
METHODS
DS was obtained as a gift sample from Indoco Remedies, Verna, Goa. PH 
was obtained as a gift sample from Merck India Ltd., Usgao Tisk Goa. 
HPMC E15, E5, and E3 were provided as a gift sample from Colorcon 
Asia Pvt. Ltd., Verna, Goa. Ascorbic acid was purchased from Avra 
synthesis Pvt. Ltd., and sucralose was obtained as gift sample from J K 
Sucralose. PEG 400 was purchased from Hi-Media Pvt., Ltd. Citric acid 
and raspberry syrup were purchased from SD Fine Chemicals. Distilled 
water prepared using in-house plant was used for the research work.
© 2018 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2018.v11i12.27978
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Fig. 1: Pyridoxine hydrochloride
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Analysis of drug
Simultaneous equation method was used in the estimation of drugs DS 
and PH. 10 ppm solution of both the drugs was prepared in simulated 
salivary fluid (SSF), and their spectra were recorded using ultraviolet 
(UV) spectrophotometer (UV 1800 Shimadzu). From the overlay 
spectra, the wavelength selected for estimation was the absorption 
maxima of both the drugs 260.6 nm and 324 nm, respectively, for DS 














CX = concentration of DS A1 = absorbance of samples at 260.6 nm 
ax1 = absorptivity of DS at 260.6 nm and ax2 = absorptivity of DS 
at 324 nm CY = concentration of PH A2 = absorbance of samples at 
324.0 nm ay1 = absorptivity of PH at 260.6 nm and ay2 = absorptivity 
of PH at 324 nm.
Preliminary screening of polymers and plasticizers
Experimental trials were carried out to find the film-forming capacity 
of various HPMC polymers, namely E15, E6, E5, and E3. The polymer 
HMPC E15 gave good films in the concentration range between 3 and 
7%, while E3, E6, and E5 gave at above 5%. The results of the placebo 
batches indicated HPMC E15 and E5 used in combination gave good 
transparent, non-tacky films of adequate stiffness with PEG 400 as 
plasticizer. Preliminary trials were carried out for the selection of 
plasticizer from PEG 400, glycerine, and propylene glycol. Glycerine 
produced tacky films while propylene glycol films were not easy to peel. 
PEG 400 when used produced easily peelable non-tacky films and was 
hence selected for the formulation.
Experiment design
An experimental design of eight formulations was set up using three 
factors at two levels. The factors as independent variable chosen were 
the concentration of HPMC E15 (X1), concentration of HPMC E5 (X2), 
and concentration of PEG 400 (X3). The responses, disintegration time 
in seconds (Y1), tensile strength measured in kg/cm2 (Y2), and drug 
release in percentage (%) of the drug DS (Y3) and PH (Y4) were chosen 
as dependant variables. Table 1 gives the layout of the experimental 
design.
Method of preparing film
The dose of DS and PH is 10 mg each. The area of 9-cm diameter Petri 
plate is 63.585 cm2. Amount of drug present in film of 4 cm2 is 10 mg, 
so total amount of each drug to be added to the 10 mL solution is 
63.585 × 10/4 = 158.96 mg.
The polymers were placed overnight for hydration in half the amount 
of water. Then, the polymer solution was made homogeneous by 
stirring it using magnetic stirrer (Remi Mumbai). Then, raspberry 
syrup, sucralose, citric acid, and ascorbic acid were added. Both the 
drugs were dissolved in water and added to the polymer solution. 
Once uniform, the formulation was casted on 9-cm diameter Petri plate 
which was previously lubricated with glycerine. The films were dried 
in oven at temperature of 38°C. The films when dried were peeled off 
using a sharp knife and then cut in 2 cm × 2 cm size. The films were then 
wrapped in aluminum foil and stored in desiccators.
Drug excipient compatibility
The compatibility of the formulation in the solid state was checked 
using differential scanning calorimetry (DSC) of making Universal V4SA 
TA Instrument in a nitrogen atmosphere with a heating rate of 1°C/min 
at a temperature between −100 and 400°C.
Evaluation
The prepared films were evaluated for physical appearance, weight, 
thickness surface pH, disintegration time, drug content, folding 
endurance, tensile strength, in vitro release, and ex vivo permeation 
studies. The physical appearance of the film such as homogeneity, 
color, transparency, and tackiness of the films was checked by visual 
inspection. Three films were weighed using Sartorius electronic 
balance (Shimadzu, Japan), and average and standard deviation were 
calculated. The thicknesses of the three films at three locations per film 
were determined using micrometer (Mitutoyo, Japan). The average 
and standard deviation were recorded. Surface pH was determined by 
placing a drop of water on the film and determined the pH by placing an 
electrode on it [6]. The disintegration time was determined using the 
disintegration test apparatus IP (Veego Instruments, Mumbai India). 
For the drug content, the film was dissolved in SSF, and then, dilutions 
were made and absorbance recorded and drug content was determined 
using UV spectrophotometer (UV 1800 Shimadzu, Japan) by method 
developed using simultaneous equation method. Folding endurance 
was determined by folding the cut films in the same plane until they 
developed cracks and the times it is folded without causing crack 
are recorded as folding endurance. Tensile strength was determined 
using the formula load at fracture multiplied by hundred divided by 
the product of film thickness and film width. In vitro drug release was 
determined using a modified dissolution method (Veego Instruments, 
Mumbai India) as stated in Dinge et al. using 20 mL of SSF as dissolution 
medium with speed of 50 rpm and temperature of 37°C [7].
Statistical analysis
The data obtained are analyzed using Design Expert 11.0 Software Trial 
version from Stat ease Inc. The contribution of each factor and its effect 
on response is obtained using ANOVA and response surface graphs. The 
significance level was considered to be p<0.05 [8].
Ex vivo permeation
The study was carried out for the best-optimized formulation using 
the excised buccal mucosa of goat using modified Franz diffusion cell. 
The buccal mucosa of freshly killed goat was obtained from the local 
slaughterhouse. The mucosa was evenly trimmed and then washed 
with Ringer’s solution. The modified Franz diffusion cell consisted of 
Fig. 2: Doxylamine succinate
Table 1: Three factor two‑level factorial experimental designs
Code Coded 
values
Actual values in 
percentage (%)
Dependent variables
X1 X2 X3 X1 X2 X3 Y1 Y2 Y3 Y4
DP1 −1 −1 −1 3 0.5 2 77.66 77.04 96 90.26
DP2 +1 −1 −1 5 0.5 2 94 139.12 89 84.54
DP3 −1 +1 −1 3 1 2 109.33 84.07 75.75 81.91
DP4 +1 +1 −1 5 1 2 130 141.9 68.35 59.51
DP5 −1 −1 +1 3 0.5 4 100.66 43.32 97.64 94.28
DP6 +1 −1 +1 5 0.5 4 165 101.53 90.21 85.27
DP7 −1 +1 +1 3 1 4 138.33 52.39 82.82 75.82
DP8 +1 +1 +1 5 1 4 174.66 108.27 78.95 69.27
X1 is % of HPMC E15 X2 is the % HPMC E5, X3 is % of PEG 400 Y1 is 
disintegration time in seconds, Y2 is tensile strength in kg/cm2, Y3 and Y4 are 
drug release at 21 min of DS and PH, respectively
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a beaker containing 20 ml of SSF warmed at 37°C which served as a 
receptor compartment. A test tube with 2 cm diameter was cut to 
obtain a cylinder which was open on both the ends to which the treated 
buccal mucosa was attached which acted as a donor compartment. 
The assembly was placed on a magnetic stirrer (Remi make). The 
film was placed on the inner side of the buccal mucosa which was 
mounted between the donor and receptor compartment. To the donor 
compartment containing the film, 1 mL of SSF was added. The receptor 
medium was stirred using magnetic bead. Samples of 2 mL were 
withdrawn at 3, 6, 9, 12, 15, 18, 21, and 24 min and replaced with 2-ml 
SSF at each time point. The absorbance was measured at 260.6 nm 
and 324 nm, and the drug permeation across the buccal mucosa was 
estimated using simultaneous equation method [8].
Stability study was done on the optimized formulation. The films 
were wrapped in aluminum foil and stored at room temperature and 
40°C ± 2°C and 75% ± 5% RH for 3 months. They were evaluated for 
appearance, weight, thickness, folding endurance, disintegration time, 
drug content, and drug release.
RESULTS AND DISCUSSION
Method for the estimation of drugs
The wavelength selected for simultaneous equation method is as shown 
in Fig. 3.
• Two simultaneous equations using absorptivity coefficients were 
formed as follows:
• A1 = 00.00956C1+0.00015C2
• A2 = 0.01545C1+0.0352C2, where A1 and A2 are absorbances of 
solution and C1 and C2 concentrations of DS and PH in mcg/mL. 
Hence, concentration of the drug can be calculated as follows:
C
A2 1545   A1 352
 3341
DS =
( ) − ( )
−





A1 15   A2 956
3341
PH =
( ) − ( )
−





Trials carried out of placebo films depict that HPMC E15 produced good 
peelable films in comparison to HPMC E5 and E3 when used alone but had 
low tensile strength at the lowest concentration of 3%. Combination of 
HPMC E15 and E5 with HPMC E15 at high concentration of 3% and HPMC 
E5 at low concentration 0.5–1% gave better results than the reverse 
combination, respectively. Results of the trials are tabulated in Table 2.
Optimized factorial design
Based on the trials of placebo batch, the concentration of HPMC E15, 
E5, and Plasticizer PEG400 at two levels was chosen as factors for 
experimental design as shown in Table 1.
Drug excipient compatibility
The DSC spectra of the pure drugs DS, PH combination of drugs DS-
PH, and combination of both drugs with excipients are as shown in 
Figs. 4-7, respectively. The spectra of the pure drug DS and PH show 
sharp endothermic peak at 100.90°C and 206.7°C, respectively. The 
combination of DS-PH spectra shows a slight shift in endothermic peak 
of DS at 102.48°C and PH at 210.80°C. The spectra of a combination of 
DS-PH and excipients show endothermic peak of DS at 100.27°C and 
PH at 197.54°C. The slight shift in the endothermic peak of PH may be 
due to change in glass transition temperature of polymers. There is 
no major change in spectra which rules out the possibility of any drug 
excipient incompatibility.
Evaluation of films
The prepared films were evaluated for weight, thickness, folding 
Fig. 3: Overlay spectra of doxylamine succinate and pyridoxine 
hydrochloride in simulated salivary fluid
Table 2: Preliminary trial of placebo films
Ingredients F1 F2 F3 F4 F5 F6 F7 F8 F9
HPMC E15 3 - - 0.5 3 3 0.5 1 3
HPMC E5 - 3 - - 0.5 1 3 3 -
HPMC E3 - - 3 3 - - - - 0.5
PEG400 2 2 2 2 2 2 2 2 2
Water 10 10 10 10 10 10 10 10 10
Film property +++ ++ + + +++ +++ ++ ++ ++
+++: Good peelable films with good tensile strength. ++: Peelable films having 
low tensile strength. +: Films difficult to peel
Fig. 4: Differential scanning calorimetry spectra of doxylamine 
succinate
Fig. 5: Differential scanning calorimetry spectra of pyridoxine 
hydrochloride
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endurance, percent elongation. and assay of film; the results are 
tabulated in Table 3. All the mouth dissolving sublingual films were 
found to be homogenous, transparent, non-tacky, easy to peel, and 
having adequate tensile strength. The films were found to weigh in 
the range of 145.66–180 mg. The thickness of the films was found to 
be between 0.246 mm and 0.326 mm. The folding endurance of all the 
formulations was found to be very good, i.e., between 898 and 1247, 
which indicate they are very robust. The percent elongation of the films 
was found to be in the range of 1.25–6.25%. The drug content in the 
films was found to be between 97.46% and 100.99% for DS and 97.49% 
and 100.65 for PH. The surface pH of the films was found to be between 
6.0 and 6.9. The drug release profile of the film formulations is shown in 
Figs. 8 and 9 for DS and PH, respectively. The formulation DP1 and DP5 
were found to release the drug completely in 21 min and DP6 in 24 min, 
while all other formulations showed complete release in 30 min. DP1 
and DP5 were found to release around 74–80% drug in 12 min.
Statistical analysis
Effect of formulation variables on disintegration time
The polynomial equation generated as per coded factors for response 1 
that is disintegration time in second is as given follows:
Y1 = +44.3575 -6.6625 *X1+ 57.50*X2–10.87250*X3 + 7.9575*X1*X3
 (1)
Where X1 is a concentration of polymer 1, X2 is a concentration of 
polymer 2, and X3 is concentration of plasticizer. The p value was 
found to be 0.0130 which is <0.05 (Table 4) that indicates that model 
is significant and the X1, X2, and X3 were found to be significant model 
terms as their p value was found to be <0.05. The effect of independent 
variables on disintegration time is shown in response surface plot 
(Figs. 10 and 11). The disintegration time of the films increased with 
increase in the concentration of HPMC E15 and E5. The concentration 
of HPMC E15 was found to have a greater effect than HPMC E5 on 
disintegration time. Similarly, increase in the concentration of PEG400 
and HPMC E15 was found to increase the disintegration time of films.
Fig. 6: Differential scanning calorimetry spectra of doxylamine 
succinate and pyridoxine hydrochloride
Fig. 7: Differential scanning calorimetry spectra of combination of 
doxylamine succinate, pyridoxine hydrochloride, and excipients
Fig. 8: Drug release of doxylamine succinate from mouth 
dissolving film formulations DP1‑8
Fig. 9: Drug release of pyridoxine hydrochloride from mouth 
dissolving film formulations DP1‑ DP8
Table 3: Physicochemical evaluation of films
Code Weight (mg)a Thicknessa (mm) Folding endurancea Percent elongationa Assay (%) DSa Assay (%) PHa
DP1 145.66±3.055 0.246±0.011 898.0±3.0 1.25±0 97.65±0.963 100.65±1.035
DP2 161.0±2.0 0.316±0.005 932.33±2.516 3.33±0.72 98.41±0.870 99.06±0.697
DP3 146.0±3.0 0.25±0.01 980.0±2.00 2.5±1.25 100.95±2.053 97.49±0.212
DP4 154.66±1.527 0.266±0.005 1053.66±3.21 3.75±1.25 98.95±0.843 98.3±1.433
DP5 167.03±1.732 0.29±0.01 1154.0±2.0 5±3.30 97.46±0.848 98.99±0.681
DP6 166.33±2.309 0.306±0.011 1207.33±2.516 6.25±0 100.74±1.087 97.84±0.371
DP7 171.66±1.527 0.29±0.017 1247.33±2.516 2.08±1.44 99.88±1.147 98.21±1.232
DP8 180.0±0.001 0.326±0.011 1274.0±3.60 4.16±1.44 100.99±1.532 98.40±0.829
aMean±SD n=3
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Effect of formulation variables on tensile strength
The polynomial equation generated as per coded factors for response 2 
that is tensile strength in kg/cm2 is as given below:
Y2 = +18.08 + 29.25 *X1+12.81*X2-17.07750*X3 (2)
The model for the response was found to be significant as the p value was 
<0.05 (Table 4). The terms X1, X2, and X3 were found to be significant 
model terms as their p value was found to be <0.05. The effect of 
independent variables on tensile strength is shown in response surface 
plot (Figs. 12 and 13). The tensile strength of the films increased with 
increase in the concentration of HPMC E15 and E5. The concentration 
of HPMC E15 was found to have greater effect than HPMC E5 on tensile 
strength. However, increase in the concentration of PEG400 with HPMC 
E15 was found to decrease the tensile strength of films.
Effect of formulation variables on drug release
The polynomial equation generated as per coded factors for response 
3 [Y3] and 4 [Y4] that is percent drug released for the drug DS and PH, 
respectively, is as given below:
Table 4: Model summary statistics of ANOVA analysis
Response p value R2 Adjusted R2 Predicted R2 Adequate precision SD CV%
Y1 0.0130 0.9696 0.9290 0.7835 14.4875 9.17 7.42
Y2 00001 0.9984 0.9972 0.9937 73.3102 1.91 2.04
Y3 0.0005 0.9967 0.9924 0.9767 38.9447 0.8977 1.06
Y4 0.0019 0.9179 0.8851 0.7899 11.9711 4.08 5.03
Fig. 11: Response surface plot for the influence of polymer and 
plasticizer on disintegration time
Fig. 12: Response surface plot for the influence of polymer on 
tensile strength
Fig. 13: Interaction plot of effect of plasticizer on tensile strength
Y3 = +132.885–2.84*X1-58.36*X2–3.61*X3+7.95*X2*X3 (3)
Y4 = +131.78750–5.96*X1-35.92*X2 (4)
The model for drug release was found to be significant as the p value 
was <0.05 (Table 4). The terms X1, X2 X3, and X2*X3 were found to be 
significant model terms for Y3 as their p value was found to be <0.05 
while for Y4, X1, and X2 were found to be the significant model terms. 
In equation Y3, X1, X2, and X3 were found to have an antagonistic effect 
on drug release as shown by the negative value in the equation −2.84, 
58.36, and −3.61 for X1, X2, and X3, respectively, while factors X2 and 
X3 in combination were found to have synergistic effect on drug release 
as shown by positive value +7.95 in the equation [9]. The influence of 
independent variables on drug release is shown in response surface plot 
(Figs. 14-17). HPMC is a hydrophilic polymer known for controlling the 
release of drugs. The drug release of the films decreased with increase 
in the concentration of HPMC E15 and E5. Increase in concentration 
of PEG400 with HPMC E15 was found to decrease the release of drug 
Fig. 10: Response surface plot for the influence of polymer on 
disintegration time
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from the films. Hence, lower concentration of polymer and plasticizer 
would form an ideal combination to increase the release of drug from 
the films.
The statistical data obtained from ANOVA are given in Table 4. The 
coefficient of variation is <10% for all the responses which indicates 
that the model is reasonably reproducible [10]. The predicted R2 value 
was found to be in reasonable agreement with adjusted R2, i.e., <2 
for all the responses that explain the reliability of the model [11]. All 
the responses in this study show adequate precision value >4 which 
indicates adequate signal, and hence, the model is significant [10].
Optimization
Design expert software provides an option for the optimization of 
formulation by choosing a desired goal for each factor and response. 
The goal for the present study was to have minimum disintegration 
time and maximum drug release with an optimum tensile strength 
within a range for the mouth dissolving sublingual film. Based on the 
goals set for the responses, the software provided various solutions 
having desirability between zero and one. From the various solutions 
provided based on the response, one solution provided by software 
was of formulation DP1 having the desirability of 0.981, which would 
give a disintegration time of 79.12 s, tensile strength of 78.08 kg/cm2, 
and drug release of 95.915% for DS and 95.947% for PH. Hence, it was 
chosen and it provided results similar to that predicted by the software 
thatbest-optimized formulation would give, fulfilling all the goals.
Ex vivo permeation study of the optimized film formulation DP1 was 
carried out the results of which are demonstrated in Fig. 17. The films 
showed more than 80% drug permeation in time period of 15 min.
Stability test
The optimized formulation did not show any visual change in 
appearance and the results of all the tests conducted are tabulated 
in Table 5 which were found to be within limits which indicates the 
stability of the formulation.
CONCLUSION
In the present study, the use of design of experiment has helped to 
identify the influence of formulation variables on the performance 
Fig. 14: Response surface plot for the influence of polymer on 
drug release of DS
Fig. 15: Response surface plot for the influence of polymer and 
plasticizer on drug release of DS
Fig. 16: Response surface plot for the influence of polymer on 
drug release of PH
Fig. 17: Ex vivo drug permeation
Table 5: Stability test results of optimized batch
Testing Room temperature ambient humidity 40°C and 75% RH
Description Transparent, non-tacky films Transparent, non-tacky films 
Folding endurance 900±3.5 896±2.0
Disintegration time (s) 72.56±2.61 75.0±1.92
Tensile strength (kg/cm2) 77.46±1.02 78.02±1.76
Drug release (%) of DS 97.21±1.59 98.33±1.87
Drug release (%) of PH 99.09±2.81 96.20±0.71
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of mouth dissolving film. The prepared films were found to be 
homogenous, non-tacky, transparent, and easy to peel. Formulation 
variables and concentration of HPMC E15 and HPMC E5 were found 
to influence the disintegration time, tensile strength, and drug 
release from films. DP1 was found to be the best formulation having 
disintegration time of 77.66 s, tensile strength of 77.04 kg/cm2, and 
providing the drug release of 96.00% DS and 90.26% pyridoxine HCl. 
Mouth dissolving sublingual film of DS and pyridoxine HCl can be an 
effective alternative to provide rapid action and relief from NVP to 
already distressed pregnant women.
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